Withdrawals due to adverse events · adults with panic disorder
SSRIs showed no clear difference in number of dropouts due to adverse events compared with naSSAs (low certainty).
1 finding from 1 review
Peritonitis · patients receiving PD
Angiotensin receptor blockers (ARBs) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (low certainty).
1 finding from 1 review
Peritonitis · patients receiving PD
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (moderate certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes maternal Grade 3/4 Severe Adverse Events compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (very low certainty).
1 finding from 1 review
Adverse events due to periodontal therapy · Patients with cardiovascular disease and chronic periodontitis
1 finding from 1 review
Adverse events: because of variable follow-up (6 to 25 months) and almost 90% loss to follow-up by one year, results were not considered useful for analysis; uncertain whether adverse events are more likely with either…
1 study · 303 participants
GRADE not reported
Treatment cessation due to adverse events · CRRT
Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment cessation due to adverse events · CRRT
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
1 finding from 1 review
Adverse events of antifibrinolytic agents · People with a haematological disorder
1 finding from 1 review
Intervention not reported
Adverse events Grade 3 or 4 adverse event · patients with HIV infection or exposure
The intervention showed no clear difference in adverse events Grade 3 or 4 adverse event (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
Hydrocortisone showed no clear difference in dropouts due to adverse events at 3 months compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (diabetes mellitus) · people undergoing pancreaticoduodenectomy
1 finding from 1 review
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in adverse events: all grades within 6 months compared with placebo (low certainty).
2 findings from 1 review
Serious adverse events until data cut‐offb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in serious adverse events until data cut‐offb compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in adverse events: all grade within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Adverse events: serum calcium above normal · relatively healthy postmenopausal women
Vitamin D plus calcium showed no clear difference in adverse events: serum calcium above normal compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Major adverse cardiovascular events (MACE) · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention probably leads to lower major adverse cardiovascular events (MACE) (moderate certainty).
1 finding from 1 review